Michael Doumas Selected Research

Vitamin E

1/2020	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
1/2018	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
1/2018	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Doumas Research Topics

Disease

39	Hypertension (High Blood Pressure) 01/2022 - 05/2006
34	Type 2 Diabetes Mellitus (MODY) 11/2023 - 03/2015
28	Heart Failure 01/2023 - 01/2016
19	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 02/2013
18	Non-alcoholic Fatty Liver Disease 01/2022 - 06/2015
15	COVID-19 03/2024 - 01/2020
10	Stroke (Strokes) 01/2022 - 04/2009
10	Chronic Renal Insufficiency 01/2022 - 10/2014
7	Hyperaldosteronism (Conn Syndrome) 01/2022 - 06/2008
6	Inflammation (Inflammations) 03/2024 - 10/2006
6	Erectile Dysfunction 11/2020 - 03/2006
6	Body Weight (Weight, Body) 12/2019 - 01/2017
5	Diabetes Mellitus 01/2022 - 03/2008
5	Atrial Fibrillation 01/2022 - 11/2013
5	Alcoholic Fatty Liver 01/2021 - 07/2015
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2023 - 07/2015
4	Albuminuria 01/2021 - 01/2017
4	Fibrosis (Cirrhosis) 01/2021 - 01/2011
4	Dyslipidemias (Dyslipidemia) 04/2018 - 09/2016
4	Thrombosis (Thrombus) 01/2018 - 10/2006
3	Overweight 12/2023 - 01/2022
3	Obesity 06/2023 - 01/2018
3	Systemic Scleroderma (Systemic Sclerosis) 04/2023 - 11/2011
3	Disease Progression 02/2023 - 10/2020
3	Myocardial Infarction 01/2022 - 05/2021
3	Infections 11/2021 - 01/2018
3	Essential Hypertension 01/2019 - 03/2006
3	Fatty Liver 04/2018 - 01/2018
3	Neoplasms (Cancer) 01/2012 - 01/2011
2	Respiratory Insufficiency (Respiratory Failure) 03/2024 - 10/2021
2	Pneumonia (Pneumonitis) 03/2024 - 02/2023
2	Weight Loss (Weight Reduction) 11/2023 - 01/2018
2	Hypoglycemia (Reactive Hypoglycemia) 11/2023 - 12/2019
2	Acute Kidney Injury (Acute Renal Failure) 09/2023 - 07/2021
2	Cardiac Arrhythmias (Arrythmia) 07/2023 - 10/2021
2	Hyperglycemia 06/2023 - 01/2018
2	Atherosclerosis 04/2023 - 01/2018
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 01/2020
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 01/2022
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 01/2017
2	Obstructive Sleep Apnea 01/2020 - 01/2017
2	Liver Diseases (Liver Disease) 04/2018 - 01/2018
2	Hepatocellular Carcinoma (Hepatoma) 04/2018 - 01/2018
2	Adenoma (Adenomas) 01/2018 - 01/2012

Drug/Important Bio-Agent (IBA)

35	Glucose (Dextrose)FDA LinkGeneric 11/2023 - 01/2017
31	SodiumIBA 09/2023 - 01/2012
25	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 05/2006
19	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2023 - 02/2013
12	Glucagon-Like Peptide-1 Receptor AgonistsIBA 07/2023 - 01/2018
11	Hypoglycemic Agents (Hypoglycemics)IBA 11/2023 - 01/2017
10	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2023 - 01/2017
6	Biomarkers (Surrogate Marker)IBA 04/2023 - 01/2020
6	Mineralocorticoid Receptor AntagonistsIBA 08/2022 - 01/2017
6	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2018
5	Glucagon-Like Peptide 1 (GLP 1)IBA 06/2023 - 01/2018
5	SymportersIBA 08/2022 - 01/2017
5	sacubitril and valsartan sodium hydrate drug combinationIBA 08/2022 - 01/2017
5	Atorvastatin (Lipitor)FDA Link 01/2021 - 01/2018
5	Rosuvastatin Calcium (Crestor)FDA Link 01/2021 - 07/2015
5	Pioglitazone (Actos)FDA Link 01/2020 - 01/2017
4	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 03/2024 - 10/2021
4	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2023 - 01/2021
4	empagliflozinIBA 08/2022 - 01/2017
4	oxidized low density lipoproteinIBA 03/2018 - 01/2017
4	LipidsIBA 01/2018 - 03/2008
4	DiureticsIBA 11/2017 - 06/2008
3	tirzepatideIBA 12/2023 - 01/2022
3	Insulin (Novolin)FDA Link 06/2023 - 01/2018
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 02/2023 - 10/2021
3	PlasminogenIBA 02/2023 - 10/2021
3	Angiotensin Receptor AntagonistsIBA 10/2020 - 05/2006
3	Vitamin E FDA LinkGeneric 01/2020 - 01/2018
3	Spironolactone (Aldactone)FDA LinkGeneric 01/2020 - 06/2008
3	LDL CholesterolIBA 03/2018 - 01/2017
3	EnzymesIBA 01/2018 - 01/2018
2	Janus Kinase InhibitorsIBA 04/2024 - 11/2021
2	Urokinase Plasminogen Activator ReceptorsIBA 03/2024 - 10/2021
2	HDL CholesterolIBA 04/2023 - 03/2018
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2023 - 05/2008
2	IronIBA 01/2023 - 01/2020
2	dapagliflozinIBA 08/2022 - 12/2019
2	semaglutideIBA 02/2022 - 01/2022
2	finerenoneIBA 01/2022 - 01/2017
2	Colchicine FDA LinkGeneric 01/2022 - 01/2020
2	ElementsIBA 12/2021 - 01/2014
2	Allopurinol (Remid)FDA LinkGeneric 01/2021 - 01/2021
2	Cardiovascular AgentsIBA 01/2021 - 02/2013
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2021 - 01/2020
2	Bisoprolol (Concor)FDA LinkGeneric 01/2020 - 03/2006
2	Metoprolol (Toprol-XL)FDA LinkGeneric 01/2020 - 03/2006
2	Ezetimibe (Zetia)FDA Link 01/2019 - 01/2017
2	Triglycerides (Triacylglycerol)IBA 03/2018 - 07/2015
2	AldosteroneIBA 01/2018 - 01/2012

Therapy/Procedure

28	Therapeutics 03/2024 - 05/2006
9	Sympathectomy (Sympathectomies) 10/2021 - 02/2010
5	Denervation 01/2020 - 11/2011
4	Catheters 01/2020 - 02/2010
4	Glycemic Control 12/2019 - 03/2015
3	Adrenalectomy 01/2022 - 01/2018
2	Secondary Prevention 01/2021 - 01/2017